Australia's most trusted
source of pharma news
Posted 7 December 2021 AM
Pressure is mounting from generics manufacturers seeking to launch competitors to blockbuster brands as early as possible, and have patents declared invalid.
In response, pharmas are suing generics companies for threatening to infringe patents, and relying on patents for manufacturing and administration processes to delay the 'first generic' approved by the Therapeutic Goods Administration, which would trigger a price reduction under the Pharmaceutical Benefits Scheme.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.